OverviewSuggest Edit

Medistim is involved in intraoperative ultrasonic guidance and quality assessment focused on improving surgical outcomes. With the MiraQ platform, Medistim offers the unique combination of transit time flow measurement (TTFM) and high-frequency ultrasound imaging. The Company provides quality control applications for use in the operating theatre during cardiac and vascular surgery.
HQOslo, NO

Latest Updates

Employees (est.) (Sept 2020)112
Share Price (Oct 2020)KR226 (+2%)
Cybersecurity ratingAMore

Key People/Management at Medistim

Lars Rønn

Lars Rønn

Board Member
Siri Fürst

Siri Fürst

Board Member
Kari Eian Krogstad

Kari Eian Krogstad

President and CEO,
Thomas Jakobsen

Thomas Jakobsen

Mike Farbelow

Mike Farbelow

Show more

Medistim Office Locations

Medistim has offices in Oslo, Horten, Plymouth, Vedbæk and in 3 other locations
Oslo, NO (HQ)
94 Økernveien
Horten, NO
Bromsveien 17
Vedbæk, DK
Gøngetoften 13
Oberhaching, DE
Bahnhofstraße 32
Barcelona, ES
Carrer de Balmes, 173, 4, 2
West Bridgford, GB
Wilford Rd
Show all (7)

Medistim Financials and Metrics

Medistim Revenue

Market capitalization (23-Oct-2020)


Closing stock price (23-Oct-2020)

Medistim's current market capitalization is kr4.1 b.
Show all financial metrics

Medistim Cybersecurity Score

Cybersecurity ratingPremium dataset



SecurityScorecard logo

Medistim Online and Social Media Presence

Embed Graph

Medistim Blogs

Benefits of Medistim technology in Carotid Endarterectomy published in EJVES

The CIDAC study is a prospective trial comparing high-frequency ultrasound (HFUS, named IDUS in the study) and angiography in 150 patients as intraoperative completion control after removal of plaque in a neck artery, a procedure called carotid endarterectomy (CEA).  The aim of a CEA procedure is to…

Results for the First Quarter 2020

Sales for the quarter ended at a record high MNOK 103.1 (MNOK 88.7), a 16.2% increase.This was driven by strong growth in capital sales of systems in Japan after regulatory approval of MiraQ™. Read the full report and presentation below. 1.quarter 2020 report Medistim Q1 2020 presentation   The post…

Company Presentation April 2020

The post Company Presentation April 2020 appeared first on Medistim.

The REQUEST study is now published

The REQUEST study is a multicenter, prospective study among 7 international centers performing coronary artery bypass grafting procedures.  The primary endpoint was any change in the planned surgical procedure. Major secondary endpoints consisted of the rate and reason for surgical changes related t…

Results for Fourth Quarter and Preliminary Results for Medistim for 2019

Sales for the quarter ended at MNOK 95.7 (MNOK 97.9), while sales for 2019 ended at MNOK 363.7 (MNOK 325.9), a growth of 11.6%. Q4 2019 PresentationQ4 and preliminary year-end financials 2019 The post Results for Fourth Quarter and Preliminary Results for Medistim for 2019 appeared first on Medistim…

Investor Presentation, March 3

Medistim’s CEO Kari E. Krogstad will hold an investor presentation at the Carnegie Healthcare Seminar 2020 in Stockholm, Sweden. Date: Tuesday March 3, 2020 Venue: Regeringsgatan 56. 103 38 Stockholm For more information about this seminar, contact https://www.carnegie.se/en/ The post Investor Prese…
Show more

Medistim Frequently Asked Questions

  • When was Medistim founded?

    Medistim was founded in 1984.

  • Who are Medistim key executives?

    Medistim's key executives are Lars Rønn, Siri Fürst and Kari Eian Krogstad.

  • How many employees does Medistim have?

    Medistim has 112 employees.

  • Who are Medistim competitors?

    Competitors of Medistim include Vycor Medical, SentreHEART and Episurf Medical.

  • Where is Medistim headquarters?

    Medistim headquarters is located at 94 Økernveien, Oslo.

  • Where are Medistim offices?

    Medistim has offices in Oslo, Horten, Plymouth, Vedbæk and in 3 other locations.

  • How many offices does Medistim have?

    Medistim has 7 offices.